Women’s Health Market Top Manufacturers, Growth, Trends, Competitive Landscape, Price and Forecasts to 2025
The health of women and girls is of particular concern because in many societies they are disadvantaged by judgment rooted in sociocultural factors. The general practice management of women’s health involves a general patient-centered approach toward the physical, mental, and emotional health of women, their families, and their relationships.
The health of women and girls is of particular concern because in many societies they are disadvantaged by judgment rooted in sociocultural factors. The general practice management of women’s health involves a general patient-centered approach toward the physical, mental, and emotional health of women, their families, and their relationships.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
With many countries pitching for improving the healthcare facilities for women, the market for women’s health will
have a positive viewpoint in the years to come. As a part of social security measure many countries have considerably
increased their healthcare budgets. The U.S. government spent 17% of their GDP on the healthcare sector in 2014.
Get a Sample Copy of This Report @
https://www.millioninsights.com/industry-reports/womens-health-market/request-sample
Women’s Health Market is segmented on the basis of application and analysis, drug class, and region. Segmentation
by application and analysis of women’s health market covers Postmenopausal osteoporosis, Infertility, Endometriosis,
Contraceptives, Menopause, Polycystic ovary syndrome (PCOS). Endometriosis is a problem affecting a woman’s
uterus; the place where a baby grows when a woman is pregnant. The misplaced tissue can cause pain, infertility, and
very heavy periods. Polycystic ovary syndrome happens when a woman’s ovaries or adrenal glands produce more male
hormones than normal.
Women with PCOS are at higher risk of developing diabetes and heart disease. Women who can get pregnant but
unable to stay pregnant is also considered as infertile. About 10% (6.1 million) of women in United States aged 15-44
years have difficulty getting pregnant or staying pregnant. A woman has reached menopause when she has not had a
period for 12 months in a row (45-55 age). Menopause happens because the woman’s ovary stops producing the
hormones estrogen and progesterone.
Contraception is a method of birth control available to prevent unintended pregnancy. Osteoporosis is of major
concern among post-menopausal women and this disease is projected to affect around 20 percent of post-menopausal
women. The disease is characterized by substantial loss of bone mass and increasing the risk of serious fractures.
Currently the menopause therapeutics market is determined by hormone therapeutics. In 2015, the postmenopausal
osteoporosis segment conquered the market and accounted for more than 37% of the market share.
Market size by drug class includes Evista, Xgeva, Mirena, Zometa, Minastrin 24FE, Nuvaring, Forteo, Premarin, Actonel,
Ortho-Tri-Cy LO 28, and Reclast. On the basis of geography, women’s health therapeutics market size comprises four
major regions: North America, Europe, Asia Pacific, and Rest of the World. North America and Europe are the foremost
markets for women health therapeutics. This is because of increased awareness regarding women health.
Contraception and fertility control are supported by the governments of developing countries such as India and China
to curb the growing population. This trend is expected to show positive growth of women’s health market from 2014
to 2025.
The key players of women’s health market are Allergan, Bayer Healthcare, Merck, Pfizer, Teva Pharmaceuticals, Agile
Therapeutics, Amgen, Apothecus Pharmaceutical, AstraZeneca, Blairex Laboratories, Bristol-Myers Squibb, Ferring
International Center.
Market Segmentation
Change language